Gelatin nanoparticles: A potential candidate for medical applications

Nanotechnology Reviews

Volumn 6, Issue 2, 2017, Pages 191-207

  Yasmin, Rehana ^a   Shah, Mohsin ^b   Khan, Saeed Ahmad ^c   Ali, Roshan ^b  

^a Tobe Camp University Road Abbottabad   (Pakistan)

^b KHYBER MEDICAL UNIVERSITY   (Pakistan)

^c KOHAT UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

Author keywords

drug delivery; gelatin nanoparticles (GNPs); medical applications; protein nanoparticles

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABILITY; BIOLOGICAL ORGANS; DISEASES; DRUG DELIVERY; GENE TRANSFER; HISTOLOGY; MEDICAL APPLICATIONS; NANOPARTICLES; PROTEINS; SCAFFOLDS (BIOLOGY); SEMICONDUCTOR QUANTUM DOTS; TISSUE;

ARTIFICIAL TISSUES; BIODEGRA-DABLE MATERIALS; BIOMEDICAL SCIENCE; BLOOD-BRAIN BARRIER; BRAIN DISORDERS; GELATIN NANOPARTICLES; MACROPHAGE TARGETING; PROTEIN NANOPARTICLES;

TARGETED DRUG DELIVERY;

EID: 85017306166     PISSN: 21919089     EISSN: 21919097     Source Type: Journal    
DOI: 10.1515/ntrev-2016-0009     Document Type: Review

References (156)

1. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47, 65-81
2. Vijayanathan V, Thomas T, Thomas T. DNA nanoparticles, and development of DNA delivery vehicles for gene therapy. Biochemistry 2002, 41, 14085-14094
3. Buzea C, Pacheco II, Robbie K. Nanomaterials, and nanoparticles: sources, and toxicity. Biointerphases 2007, 2, MR17-MR71
4. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug, and gene delivery to cells, and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347. Osteoclast Osteoblast QDs-GNS-Anti-lgG Osteosarcoma Figure 8: Imaging of QDs, and IGg decorated GNPs in the bone tumor site
5. Morimoto K, Katsumata H, Yabuta T, Iwanaga K, Kakemi M, Tabata Y, Ikada Y. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol. 2000, 52, 611-617
6. Tran PH-L, Tran TT-D, Lee B-J. Enhanced solubility, and modified release of poorly water-soluble drugs via self-Assembled gelatin-oleic acid nanoparticles. Int. J. Pharm. 2013, 455, 235-240
7. Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide)-modified poly (?-Amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution, and tumor localization studies. Pharm. Res. 2005, 22, 2107-2114
8. Khan SA. Gelatin Nanoparticles as Potential Nanocarriers for Macromolecular Drugs, Philipps University Marburg: Germany, 2014
9. Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading, and delivery. Eur. J. Pharm. Biopharm. 2010, 76, 1-9
10. Elzoghby AO. Gelatin-based nanoparticles as drug, and gene delivery systems: reviewing three decades of research. J. Controll. Release 2013, 172, 1075-1091
11. Azarmi S, Huang Y, Chen H, McQuarrie S, Abrams D, Roa W, Finlay WH, Miller GG, Löbenberg R. Optimization of a two-step desolvation method for preparing gelatin nanoparticles, and cell uptake studies in 143B osteosarcoma cancer cells. J. Pharm. Pharm. Sci. 2006, 9, 124-132
12. Sawicka J. [Microencapsulization of cholecalciferol by coacervation]. Die Pharmazie 1990, 45, 264-265
13. Bajpai A, Choubey J. In vitro release dynamics of an anticancer drug from swellable gelatin nanoparticles. J. Appl. Polymer Sci. 2006, 101, 2320-2332
14. Fraunhofer W, Winter G, Coester C. Asymmetrical flow field-flow fractionation, and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems. Anal. Chem. 2004, 76, 1909-1920
15. Saxena A, Sachin K, Bohidar H, Verma AK. Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles. Colloids Surf. B Biointerfaces 2005, 45, 42-48
16. Zwiorek K, Kloeckner J, Wagner E, Coester C. Gelatin nanoparticles as a new, and simple gene delivery system. J. Pharm. Pharm. Sci. 2004, 7, 22-28
17. Jameela S, Jayakrishnan A. Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone, and in vivo degradation of microspheres in rat muscle. Biomaterials 1995, 16, 769-775
18. Levy M-C, Andry M-C. Microcapsules prepared through interfacial cross-linking of starch derivatives. Int. J. Pharm. 1990, 62, 27-35
19. Farrugia CA, Groves MJ. Gelatin behaviour in dilute aqueous solution: designing a nanoparticulate formulation. J. Pharm. Pharmacol. 1999, 51, 643-649
20. Mohanty B, Bohidar H. Systematic of alcohol-induced simple coacervation in aqueous gelatin solutions. Biomacromolecules 2003, 4, 1080-1086
21. Mohanty B, Aswal V, Kohlbrecher J, Bohidar H. Synthesis of gelatin nanoparticles via simple coacervation. J. Surf. Sci. Technol. 2005, 21, 149
22. Marty J, Oppenheim R, Speiser P. Nanoparticles-A new colloidal drug delivery system. Pharm. Acta Helv. 1978, 53, 17
23. Leo E, Vandelli MA, Cameroni R, Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process. Int. J. Pharm. 1997, 155, 75-82
24. Choubey J, Bajpai A. Investigation on magnetically controlled delivery of doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin. J. Mater. Sci. Mater. Med. 2010, 21, 1573-1586
25. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques, and size-control parameters. Prog. Polym. Sci. 2011, 36, 887-913
26. Gupta AK, Gupta M, Yarwood SJ, Curtis AS. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology, and cytoskeleton organisation of human fibroblasts. J. Control. Release 2004, 95, 197-207
27. Lee E, Khan S, Lim K-H. Gelatin nanoparticle preparation by nanoprecipitation. J. Biomater. Sci. Polym. Ed. 2011, 22, 753-771
28. Khan SA, Schneider M. Improvement of nanoprecipitation technique for preparation of gelatin nanoparticles, and potential macromolecular drug loading. Macromol. Biosci. 2013, 13, 455-463
29. Couvreur P, Puisieux F. Nano-And microparticles for the delivery of polypeptides, and proteins. Adv. Drug Deliv. Rev. 1993, 10, 141-162
30. Hans M, Lowman A. Biodegradable nanoparticles for drug delivery, and targeting. Curr. Opin. Solid State Mater. Sci. 2002, 6, 319-327
31. Gaihre B, Khil MS, Lee DR, Kim HY. Gelatin-coated magnetic iron oxide nanoparticles as carrier system: drug loading, and in vitro drug release study. Int. J. Pharm. 2009, 365, 180-189
32. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70, 1-20
33. Santoro M, Tatara AM, Mikos AG. Gelatin carriers for drug, and cell delivery in tissue engineering. J. Control. Release 2014, 190, 210-218
34. Sahoo N, Sahoo RK, Biswas N, Guha A, Kuotsu K. Recent advancement of gelatin nanoparticles in drug, and vaccine delivery. Int. J. Biol. Macromol. 2015, 81, 317-331
35. Nahar M, Mishra D, Dubey V, Jain NK. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomed. Nanotechnol. Biol. Med. 2008, 4, 252-261
36. Van Vlerken LE, Amiji MM. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin. Drug Deliv. 2006, 3, 205-16
37. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery, and imaging: a promising avenue for cancer therapy, and diagnosis using targeted functional nanoparticles. Int. J. Cancer 2007, 120, 2527-2537
38. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2007, 59, 718-728
39. Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 1996, 13, 820-831
40. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology, and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002, 95, 2006-2016
41. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability, and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284
42. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer 2001, 1, 130-141
43. Brown R, Links M. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med. 1999, 1, 1-21
44. Lu Z, Yeh T-K, Tsai M, Au JL-S, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 2004, 10, 7677-7684
45. Li Z, Percival SS, Bonard S, Gu L. Fabrication of nanoparticles using partially purified pomegranate ellagitannins, and gelatin, and their apoptotic effects. Mol. Nutr. Food Res. 2011, 55, 1096-1103
46. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells, and primary T-lymphocytes. Biomaterials 2005, 26, 5898-5906
47. Blanco M, Trigo R, Teijón C, Gómez C, Teijón J. Slow releasing of ara-C from poly (2-hydroxyethyl methacrylate), and poly (2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone) hydrogels implanted subcutaneously in the back of rats. Biomaterials 1998, 19, 861-869
48. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96
49. Brown J, Eraut D, Trask C, Davison A. Age, and the treatment of lung cancer. Thorax 1996, 51, 564-568
50. Long J-T, Cheang T-y, Zhuo S-Y, Zeng R-F, Dai Q-S, Li H-P, Fang S. Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J. Nanobiotechnol. 2014, 12, 37
51. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions, and promises. J. Nutr. Biochem. 2005, 16, 449-466
52. Kang O-H, Jang H-J, Chae H-S, Oh Y-C, Choi J-G, Lee Y-S, Kim J-H, Kim YC, Sohn DH, Park H. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-?B, and MAPK. Pharmacol. Res. 2009, 59, 330-337
53. Karthikeyan S, Prasad NR, Ganamani A, Balamurugan E. Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomed. Prev. Nutr. 2013, 3, 64-73
54. Kim EJ, Lee Y-J, Shin H-K, Park JHY. Induction of apoptosis by the aqueous extract of Rubus coreanum in HT-29 human colon cancer cells. Nutrition 2005, 21, 1141-1148
55. Ju HK, Cho EJ, Jang MH, Lee YY, Hong SS, Park JH, Kwon SW. Characterization of increased phenolic compounds from fermented Bokbunja (Rubus coreanus Miq.), and related antioxidant activity. J. Pharm. Biomed. Anal. 2009, 49, 820-827
56. Seo YC, Choi WY, Lee CG, Cha SW, Kim YO, Kim J-C, Drummen GP, Lee HY. Enhanced immunomodulatory activity of gelatinencapsulated Rubus coreanus Miquel nanoparticles. Int. J. Mol. Sci. 2011, 12, 9031-9056
57. El-Shabouri M. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 2002, 249, 101-108
58. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog. Neurobiol. 2009, 88, 272-285
59. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-And transferrin-receptor-Antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 2009, 71, 251-256
60. Tian X-h, Lin X-N, Wei F, Feng W, Huang Z-C, Wang P, Ren L, Diao Y. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomed. 2011, 6, 445-452
61. Kreuter J. Nanoparticles - a historical perspective. Int. J. Pharm. 2007, 331, 1-10
62. Koo Y-EL, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Ross BD, Kopelman R. Brain cancer diagnosis, and therapy with nanoplatforms. Adv. Drug Deliv. Rev. 2006, 58, 1556-1577
63. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status, and future prospects. FASEB J. 2005, 19, 311-330
64. Tian X-h, Wei F, Wang T-x, Wang P, Lin X-n, Wang J, Wang D, Ren L. In vitro, and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int. J. Nanomed. 2012, 7, 1031
65. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress, and future prospects. Chem. Biol. 2012, 19, 60-71
66. Glebova K, Marakhonov A, Baranova A, Skoblov MY. Therapeutic siRNAs, and nonviral systems for their delivery. Mol. Biol. 2012, 46, 335-348
67. Ishikawa H, Nakamura Y, Jo J-i, Tabata Y. Gelatin nanospheres incorporating siRNA for controlled intracellular release. Biomaterials 2012, 33, 9097-9104
68. Kim I-D, Sawicki E, Lee H-K, Lee E-H, Park HJ, Han P-L, Kim KK, Choi H, Lee J-K. Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 1219-1229
69. Kommareddy S, Amiji M. Poly (ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomed. Nanotechnol. Biol. Med. 2007, 3, 32-42
70. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomed. Nanotechnol. Biol. Med. 2008, 4, 41-48
71. Nahar M, Dubey V, Mishra D, Mishra PK, Dube A, Jain NK. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J. Drug Target. 2010, 18, 93-105
72. Weber C, Coester C, Kreuter J, Langer K. Desolvation process, and surface characterisation of protein nanoparticles. Int. J. Pharm. 2000, 194, 91-102
73. Dwivedi P, Kansal S, Sharma M, Shukla R, Verma A, Shukla P, Tripathi P, Gupta P, Saini D, Khandelwal K. Exploiting 4-sulphate N-Acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro, and in vivo. J. Drug Target. 2012, 20, 883-896
74. Mahajan S, Prashant C, Koul V, Choudhary V, K Dinda A. Receptor specific macrophage targeting by mannose-conjugated gelatin nanoparticles-An in vitro, and in vivo study. Curr. Nanosci. 2010, 6, 413-421
75. Kaur A, Jain S, Tiwary A. Mannan-coated gelatin nanoparticles for sustained, and targeted delivery of didanosine: in vitro, and in vivo evaluation. Acta Pharm. 2008, 58, 61-74
76. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Deliv. Rev. 1995, 16, 141-155
77. Truong-Le VL, Walsh SM, Schweibert E, Mao H-Q, Guggino WB, August JT, Leong KW. Gene transfer by DNA-gelatin nanospheres. Arch. Biochem Biophys. 1999, 361, 47-56
78. Truong-Le VL, August JT, Leong KW. Controlled gene delivery by DNA-gelatin nanospheres. Hum. Gene Ther. 1998, 9, 1709-1717
79. Leong YS, Candau F. Inverse microemulsion polymerization. J. Phys. Chem. 1982, 86, 2269-2271
80. Kaul G, Amiji M. Long-circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 2002, 19, 1061-1067
81. Kommareddy S, Amiji M. Biodistribution, and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci. 2007, 96, 397-407
82. Kaul G, Amiji M. Cellular interactions, and in vitro DNA transfection studies with poly (ethylene glycol)-modified gelatin nanoparticles. J. Pharm. Sci. 2005, 94, 184-198
83. Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: in vitro, and in vivo studies. Pharm. Res. 2005, 22, 951-961
84. Barton C, Staddon S, Hughes C, Hall P, Osullivan C, Klöppel G, Theis B, Russell R, Neoptolemos J, Williamson R. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 1991, 64, 1076
85. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003, 22, 9030-9040
86. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458, 1127-1130
87. Xu J, Singh A, Amiji MM. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA, and gemcitabine in the treatment of pancreatic cancer. BMC Cancer 2014, 14, 75
88. Bardeesy N, DePinho RA. Pancreatic cancer biology, and genetics. Nat. Rev. Cancer 2002, 2, 897-909
89. Xu J, Amiji M. Therapeutic gene delivery, and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles. J. Vis. Exp. 2012, 59, e3612
90. Satoh M, Perkins E, Kimura H, Tang J, Chun Y, Heistad DD, Zhang JH. Posttreatment with adenovirus-mediated gene transfer of calcitonin gene-related peptide to reverse cerebral vasospasm in dogs. J. Neurosurg. 2002, 97, 136-142
91. Toyoda K, Faraci FM, Watanabe Y, Ueda T, Andresen JJ, Chu Y, Otake S, Heistad DD. Gene transfer of calcitonin gene-related peptide prevents vasoconstriction after subarachnoid hemorrhage. Circ. Res. 2000, 87, 818-824
92. Tian X-H, Wang Z-G, Meng H, Wang Y-H, Feng W, Wei F, Huang Z-C, Lin X-N, Ren L. Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm. Int. J. Nanomed. 2013, 8, 865
93. Wang Z-Y, Zhao Y, Ren L, Jin L-H, Sun L-P, Yin P, Zhang Y-F, Zhang Q-Q. Novel gelatin-siloxane nanoparticles decorated by Tat peptide as vectors for gene therapy. Nanotechnology 2008, 19, 445103
94. Yin P, Wang J, Ren L, Wang Z-Y, Wang T-X, Wang D, Tian M-M, Tian X-H. Conjugation of membrane-destabilizing peptide onto gelatin-siloxane nanoparticles for efficient gene expression. Mater. Sci. Engng C 2010, 30, 1260-1265
95. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 2006, 29, 558-568
96. Bourquin C, Anz D, Zwiorek K, Lanz A-L, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Moder S. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 2008, 181, 2990-2998
97. Du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res. 2006, 7, 118
98. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 2005, 172, 1487-1490
99. Saraogi GK, Gupta P, Gupta U, Jain N, Agrawal G. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int. J. Pharm. 2010, 385, 143-149
100. Carter K, Dolan T, Alexander J, Baillie A, McColgan C. Visceral leishmaniasis: drug carrier system characteristics, and the ability to clear parasites from the liver, spleen, and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol. 1989, 41, 87-91
101. Kleinberg M. What is the current, and future status of conventional amphotericin B? Int. J. Antimicrob. Agents 2006, 27, 12-16
102. Khatik R, Dwivedi P, Khare P, Kansal S, Dube A, Mishra PR, Dwivedi AK. Development of targeted 1, 2-diacyl-sn-glycero- 3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro, and in vivo effect in leishmaniasis. Expert Opin. Drug Deliv. 2014, 11, 633-646
103. Klasen H. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000, 26, 131-138
104. Rujitanaroj P-O, Pimpha N, Supaphol P. Wound-dressing materials with antibacterial activity from electrospun gelatin fiber mats containing silver nanoparticles. Polymer 2008, 49, 4723-4732
105. Rattanaruengsrikul V, Pimpha N, Supaphol P. In vitro efficacy, and toxicology evaluation of silver nanoparticle-loaded gelatin hydrogel pads as antibacterial wound dressings. J. Appl. Polym. Sci. 2012, 124, 1668-1682
106. Kim SC, Kim SM, Yoon GJ, Nam SW, Lee SY, Kim JW. Gelatinbased sponge with Ag nanoparticles prepared by solution plasma: Fabrication, characteristics, and their bactericidal effect. Curr. Appl. Phys. 2014, 14, S172-S179
107. Nakaoka R, Tabata Y, Ikada Y. Potentiality of gelatin microsphere as immunological adjuvant. Vaccine 1995, 13, 653-661
108. Janero DR, Ewing JF. Nitric oxide, and postangioplasty restenosis: pathological correlates, and therapeutic potential. Free Radical Biol. Med. 2000, 29, 1199-1221
109. Weintraub WS. The pathophysiology, and burden of restenosis. Am. J. Cardiol. 2007, 100, S3-S9
110. Costa MA, Simon DI. Molecular basis of restenosis, and drugeluting stents. Circulation 2005, 111, 2257-2273
111. Zhang QY, Wang ZY, Wen F, Ren L, Li J, Teoh SH, Thian ES. Gelatin-siloxane nanoparticles to deliver nitric oxide for vascular cell regulation: synthesis, cytocompatibility, and cellular responses. J. Biomed. Mater. Res. Part A 2015, 103, 929-938
112. Shea LD, Wang D, Franceschi RT, Mooney DJ. Engineered bone development from a pre-osteoblast cell line on three-dimensional scaffolds. Tissue Engng 2000, 6, 605-617
113. Maquet V, Boccaccini AR, Pravata L, Notingher I, Jérôme R. Porous poly (?-hydroxyacid)/Bioglass composite scaffolds for bone tissue engineering. I: preparation, and in vitro characterisation. Biomaterials 2004, 25, 4185-4194
114. Liu X, Smith LA, Hu J, Ma PX. Biomimetic nanofibrous gelatin/apatite composite scaffolds for bone tissue engineering. Biomaterials 2009, 30, 2252-2258
115. Xu X, Capito RM, Spector M. Delivery of plasmid IGF-1 to chondrocytes via cationized gelatin nanoparticles. J. Biomed. Mater. Res. Part A 2008, 84, 73-83
116. Venugopal JR, Low S, Choon AT, Kumar AB, Ramakrishna S. Nanobioengineered electrospun composite nanofibers, and osteoblasts for bone regeneration. Artif. Organs 2008, 32, 388-397
117. Li X, Xie J, Yuan X, Xia Y. Coating electrospun poly (e-caprolactone) fibers with gelatin, and calcium phosphate, and their use as biomimetic scaffolds for bone tissue engineering. Langmuir 2008, 24, 14145-14150
118. Ward AG, Courts A. Science, and Technology of Gelatin, Academic Press: New York, 1977
119. Hench LL, Wilson J. Clinical Performance of Skeletal Prostheses, Springer: Berlin, Germany, 1996
120. Hench LL, Wilson J. An Introduction to Bioceramics, World Scientific: Singapore, 1993
121. Li SH, De Wijn JR, Layrolle P, De Groot K. Synthesis of macroporous hydroxyapatite scaffolds for bone tissue engineering. J. Biomed. Mater. Res. 2002, 61, 109-120
122. Mozafari M, Moztarzadeh F, Rabiee M, Azami M, Maleknia S, Tahriri M, Moztarzadeh Z, Nezafati N. Development of macroporous nanocomposite scaffolds of gelatin/bioactive glass prepared through layer solvent casting combined with lamination technique for bone tissue engineering. Ceramics Int. 2010, 36, 2431-2439
123. Armitage GC. Periodontal diagnoses, and classification of periodontal diseases. Periodontology 2000. 2004, 34, 9-21
124. Hench LL. Bioceramics: from concept to clinic. J. Am. Ceramic Soc. 1991, 74, 1487-1510
125. Peter M, Binulal N, Nair S, Selvamurugan N, Tamura H, Jayakumar R. Novel biodegradable chitosan-gelatin/nanobioactive glass ceramic composite scaffolds for alveolar bone tissue engineering. Chem. Engng J. 2010, 158, 353-361
126. Dressler M, Dombrowski F, Simon U, Börnstein J, Hodoroaba V, Feigl M, Grunow S, Gildenhaar R, Neumann M. Influence of gelatin coatings on compressive strength of porous hydroxyapatite c eramics. J. Eur. Ceramic Soc. 2011, 31, 523-529
127. Kim HW, Knowles JC, Kim HE. Porous scaffolds of gelatin-hydroxyapatite nanocomposites obtained by biomimetic approach: characterization, and antibiotic drug release. J. Biomed. Mater. Res. Part B Appl. Biomater. 2005, 74, 686-698
128. Habraken W, De Jonge L, Wolke J, Yubao L, Mikos A, Jansen J. Introduction of gelatin microspheres into an injectable calcium phosphate cement. J. Biomed. Mater. Res. Part A 2008, 87, 643-655
129. Habraken W, Boerman O, Wolke J, Mikos A, Jansen J. In vitro growth factor release from injectable calcium phosphate cements containing gelatin microspheres. J. Biomed. Mater. Res. Part A 2009, 91, 614-622
130. Shu XZ, Liu Y, Palumbo F, Prestwich GD. Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 2003, 24, 3825-3834
131. Peattie RA, Pike DB, Yu B, Cai S, Shu XZ, Prestwich GD, Firpo MA, Fisher RJ. Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels. Drug Deliv. 2008, 15, 389-397
132. Hosack LW, Firpo MA, Scott JA, Prestwich GD, Peattie RA. Microvascular maturity elicited in tissue treated with cytokineloaded hyaluronan-based hydrogels. Biomaterials 2008, 29, 2336-2347
133. Zhao F, Yin Y, Lu WW, Leong JC, Zhang W, Zhang J, Zhang M, Yao K. Preparation, and histological evaluation of biomimetic three-dimensional hydroxyapatite/chitosan-gelatin network composite scaffolds. Biomaterials 2002, 23, 3227-3234
134. Zhao F, Grayson WL, Ma T, Bunnell B, Lu WW. Effects of hydroxyapatite in 3-D chitosan-gelatin polymer network on human mesenchymal stem cell construct development. Biomaterials 2006, 27, 1859-1867
135. Liu H, Fan H, Cui Y, Chen Y, Yao K, Goh JC. Effects of the controlled-released basic fibroblast growth factor from chitosan-gelatin microspheres on human fibroblasts cultured on a chitosan-gelatin scaffold. Biomacromolecules 2007, 8, 1446-1455
136. Mandal BB, Mann JK, Kundu S. Silk fibroin/gelatin multilayered films as a model system for controlled drug release. Eur. J. Pharm. Sci. 2009, 37, 160-171
137. Gil ES, Frankowski DJ, Spontak RJ, Hudson SM. Swelling behavior, and morphological evolution of mixed gelatin/silk fibroin hydrogels. Biomacromolecules 2005, 6, 3079-3087
138. Meng Z, Xu X, Zheng W, Zhou H, Li L, Zheng Y, Lou X. Preparation, and characterization of electrospun PLGA/gelatin nanofibers as a potential drug delivery system. Colloids Surf. B Biointerf. 2011, 84, 97-102
139. Meng Z, Wang Y, Ma C, Zheng W, Li L, Zheng Y. Electrospinning of PLGA/gelatin randomly-oriented, and aligned nanofibers as potential scaffold in tissue engineering. Mater. Sci. Engng C 2010, 30, 1204-1210
140. Kasper FK, Kushibiki T, Kimura Y, Mikos AG, Tabata Y. In vivo release of plasmid DNA from composites of oligo (poly (ethylene glycol) fumarate), and cationized gelatin microspheres. J. Control. Release 2005, 107, 547-561
141. Nejadnik MR, Mikos AG, Jansen JA, Leeuwenburgh SC. Facilitating the mineralization of oligo (poly (ethylene glycol) fumarate) hydrogel by incorporation of hydroxyapatite nanoparticles. J. Biomed. Mater. Res. Part A 2012, 100, 1316-1323
142. Holland TA, Tabata Y, Mikos AG. Dual growth factor delivery from degradable oligo (poly (ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J. Control. Release 2005, 101, 111-125
143. Kim K, Lam J, Lu S, Spicer PP, Lueckgen A, Tabata Y, Wong ME, Jansen JA, Mikos AG, Kasper FK. Osteochondral tissue regeneration using a bilayered composite hydrogel with modulating dual growth factor release kinetics in a rabbit model. J. Control. Release 2013, 168, 166-178
144. Kempen DH, Lu L, Heijink A, Hefferan TE, Creemers LB, Maran A, Yaszemski MJ, Dhert WJ. Effect of local sequential VEGF, and BMP-2 delivery on ectopic, and orthotopic bone regeneration. Biomaterials 2009, 30, 2816-2825
145. Drbohlavova J, Adam V, Kizek R, Hubalek J. Quantum dots -characterization, preparation, and usage in biological systems. Int. J. Mol. Sci. 2009, 10, 656-673
146. Yong K-T, Ding H, Roy I, Law W-C, Bergey EJ, Maitra A, Prasad PN. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 2009, 3, 502-510
147. Choi HS, Liu W, Liu F, Nasr K, Misra P, Bawendi MG, Frangioni JV. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 2010, 5, 42-47
148. Lovrić J, Bazzi HS, Cuie Y, Fortin GR, Winnik FM, Maysinger D. Differences in subcellular distribution, and toxicity of green, and red emitting CdTe quantum dots. J. Mol. Med. 2005, 83, 377-385
149. Li K, Chen J, Bai S, Wen X, Song S, Yu Q, Li J, Wang Y. Intracellular oxidative stress, and cadmium ions release induce cytotoxicity of unmodified cadmium sulfide quantum dots. Toxicol. In Vitro 2009, 23, 1007-1013
150. Byrne SJ, Williams Y, Davies A, Corr SA, Rakovich A, Gunko YK, Rakovich YP, Donegan JF, Volkov Y. "Jelly dots": synthesis, and cytotoxicity studies of CdTe quantum dot-gelatin nanocomposites. Small 2007, 3, 1152-1156
151. Prasad BR, Nikolskaya N, Connolly D, Smith TJ, Byrne SJ, Gérard VA, Gunko YK, Rochev Y. Long-term exposure of CdTe quantum dots on PC12 cellular activity, and the determination of optimum non-toxic concentrations for biological use. J. Nanobiotechnol. 2010, 8, 7
152. Gérard VA, Maguire CM, Bazou D, Gunko YK. Folic acid modified gelatine coated quantum dots as potential reagents for in vitro cancer diagnostics. J. Nanobiotechnol. 2011, 9, 50
153. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. 2011, 108, 2426-2431
154. Jiang S, Eltoukhy AA, Love KT, Langer R, Anderson DG. Lipidoid-coated iron oxide nanoparticles for efficient DNA, and siRNA delivery. Nano Lett. 2013, 13, 1059-1064
155. Tse WH, Gyenis L, Litchfield DW, Zhang J, Engineering large gelatin nanospheres coated with quantum dots for targeted delivery of human osteosarcoma with enhanced cellular internalization. In 14th IEEE International Conference on Nanotechnology 2014 Aug 18. IEEE. pp. 672-677
156. Won Y-W, Kim Y-H. Preparation, and cytotoxicity comparison of type A gelatin nanoparticles with recombinant human gelatin nanoparticles. Macromol. Res. 2009, 17, 464-468